Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sarah Wilmsmeyer

Physician Assistant, Medical Chesterfield, MO Physician Assistant

NPI 1205009552 CMS profile 10836402

15740 S Outer 40 Rd, Chesterfield, MO 63017

Open in the dashboard

General payments

$21,947

813 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sarah Wilmsmeyer of Chesterfield, MO is reported in the CMS Open Payments database as having received $21,947 across 813 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,437 133
2024 General $4,764 154
2023 General $3,160 163
2022 General $8,929 182
2021 General $2,657 181

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sarah Wilmsmeyer
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Sarah Wilmsmeyer were reported at $2,437. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Sarah Wilmsmeyer Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,657 $156 $41–$563 $132
2022 $8,929 $185 $55–$649 $149
2023 $3,160 $199 $58–$717 $160
2024 $4,764 $206 $62–$740 $164
2025 $2,437 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Scientific Affairs, LLC $6,251 14 payments
  2. Janssen Biotech, Inc. $3,965 121 payments
  3. AbbVie, Inc. $2,504 145 payments
  4. Amgen Inc. $1,902 123 payments
  5. Pfizer Inc. $1,165 84 payments
  6. Novartis Pharmaceuticals Corporation $1,111 71 payments
  7. UCB, Inc. $1,070 53 payments
  8. AstraZeneca Pharmaceuticals LP $849 40 payments
  9. Lilly USA, LLC $704 41 payments
  10. GlaxoSmithKline, LLC. $258 17 payments
  11. Other $2,166 104 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,311 801 payments
  2. Consulting Fee $5,763 2 payments
  3. Travel and Lodging $1,542 2 payments
  4. Education $331 8 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $9,527 92 payments
  2. STELARA $6,379 50 payments
  3. RINVOQ $1,842 106 payments
  4. XELJANZ $1,071 78 payments
  5. SIMPONI ARIA $1,049 68 payments
  6. SAPHNELO $849 40 payments
  7. TALTZ $704 41 payments
  8. Cimzia $621 34 payments
  9. COSENTYX $580 38 payments
  10. REMICADE $570 43 payments
  11. Other $7,445 451 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,810

Median for Physician Assistant: 241

Drug cost

$909,323

Median for Physician Assistant: $4,110

Branded share of claims

29.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 21 $382,742
Enbrel Mini Etanercept Brand 20 $179,654
Rinvoq Upadacitinib Brand 17 $107,315
Cosentyx Sensoready (2 Pens) Secukinumab Brand 14 $106,837
Kevzara Sarilumab Brand 17 $73,870
Methotrexate Methotrexate Sodium Brand 348 $10,050
Hydroxychloroquine Sulfate Generic 327 $9,692
Rasuvo Methotrexate/Pf Brand 14 $9,491
Leflunomide Generic 150 $8,618
Azathioprine Generic 43 $3,522

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$2,163 — —
RINVOQ
$459 17 —
SKYRIZI
$233 — —
Cimzia
$231 — —
COSENTYX
$218 14 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

813 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record